Join

Compare · APOP vs BAX

APOP vs BAX

Side-by-side comparison of Cellect Biotechnology Ltd. (APOP) and Baxter International Inc. (BAX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both APOP and BAX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • BAX is the larger of the two at $9.35B, about 580.2x APOP ($16.1M).
  • BAX has hit the wire 5 times in the past 4 weeks while APOP has been quiet.
  • BAX has more recent analyst coverage (25 ratings vs 0 for APOP).
MetricAPOPBAX
Company
Cellect Biotechnology Ltd.
Baxter International Inc.
Price
$13.13+1.23%
$18.15-1.44%
Market cap
$16.1M
$9.35B
1M return
-
+5.95%
1Y return
-
-40.53%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NASDAQ
NYSE
IPO
2016
News (4w)
0
5
Recent ratings
0
25
APOP

Cellect Biotechnology Ltd.

Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. The company develops ApoTainer, a kit for hematopoietic stem cell transplantation procedures. It has collaborations with the denovoMATRIX group of the Technische Universität Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in's identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state; and XNK therapeutics to focus on the development of cell-based therapeutics from NK cells. The company was formerly known as Cellect Biomed Ltd. and changed its name to Cellect Biotechnology Ltd. in July 2016. Cellect Biotechnology Ltd. was incorporated in 1986 and is headquartered in Kfar Saba, Israel.

BAX

Baxter International Inc.

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.